STEP-UP is a year-long bilingual (English-Russian) modular training programme for HIV activist/advocates in Europe and Central Asia to advance their knowledge and skills. By the end of the programme, trainees should be better equipped to:
ECAB is a high-level scientific platform that brings together civil society, scientific researchers, the pharmaceutical industry and international institutions to address key science and access issues related to HIV and its main co-infections like viral hepatitis or tuberculosis.
The overall goal of PROMise is to establish a joint framework for the consideration of HIV-specific Patient Reported Outcome Measures (PROMs) in HIV R&D in collaboration with key stakeholders from community organizations, academia, industry, regulators and Health Technology Assessment (HTA) bodies.
The STEPS workshop brings the discussion on the importance of patient involvement from the very earliest phases of the development of this innovative research. The objective is to improve participation, exchange of information and knowledge about research on therapeutic strategies for long term remission from HIV and the possible dissemination among the European activists and the community at large. The workshop presents an overview about investigational strategies used in the HIV cure and vaccines field, and analyses in depth the mechanism of persistence and intervention to eradicate or reduce the size of the HIV reservoirs.
HIVACAR aims to provide a new therapeutic alternative to “cART for life” (combined antiretroviral therapy) and will address the individual and public health limitations associated with this standard of care:
The European HIV Alliance (EHVA) is a project funded by the European Union’s Horizon 2020 Research and Innovation Programme designed to foster the development of an effective HIV vaccine.
The European Patients’ Academy on Therapeutic Innovation (EUPATI) is a multi-stakeholder public-private partnership, originally launched by the IMI-EUPATI project (2012-2017), that provides education and training to increase the capacity and capability of patients and patient representatives to understand and meaningfully contribute to medicines research and development (R&D), and to improve the availability of medical information for patients and other stakeholders.
EU-PEARL has the ambition of transforming the current approach of conducting single-compound clinical trials into the use of cross-company Integrated Research Platforms (IRPs), taking into consideration both patients’ interests and the opportunities from novel molecules for addressing medical needs.
In the first five years of operations, EATRIS has shown strong proof of concept of the value of the services portfolio, with users ranging from academia, SMEs, large pharma, to biotech and research funding organisations. The overarching aim of EATRIS-Plus is to support the long-term sustainability (LTS) of EATRIS by delivering innovative scientific tools to the research community, strengthening the infrastructure’s financial model and reinforcing EATRIS leadership in the European Research Area (ERA), particularly in the field of Personalised Medicine (PM) research and development.
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.